Cargando…

Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study

Introduction and objectives: Heart failure (HF) is a major health problem that causes high mortality and hospitalization rates. This study aims to determine the HF prevalence rates in populations aged both ≥18 years and ≥50 years and to assess its association with cardiovascular diseases and chronic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruiz-García, Antonio, Serrano-Cumplido, Adalberto, Escobar-Cervantes, Carlos, Arranz-Martínez, Ezequiel, Turégano-Yedro, Miguel, Pallarés-Carratalá, Vicente
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419820/ https://www.ncbi.nlm.nih.gov/pubmed/37568326 http://dx.doi.org/10.3390/jcm12154924

Ejemplares similares

Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study
por: Pallarés-Carratalá, Vicente, et al.
Publicado: (2023)

Vitamin D Supplementation and Its Impact on Mortality and Cardiovascular Outcomes: Systematic Review and Meta-Analysis of 80 Randomized Clinical Trials
por: Ruiz-García, Antonio, et al.
Publicado: (2023)

Elevated pulse pressure and cardiovascular risk associated in Spanish population attended in primary care: IBERICAN study
por: Moyá-Amengual, Ana, et al.
Publicado: (2023)

Vacuna COVID-19 y pacientes anticoagulados por alto riesgo cardiovascular. Recomendaciones SEMERGEN
por: Pallarés-Carratalá, V., et al.
Publicado: (2021)

Optimización del control telemático de la presión arterial en atención primaria en España (Iniciativa Óptima): resultados de un estudio Delphi
por: Sánchez Peinador, Carmen, et al.
Publicado: (2022)

Approach to Patients with Obesity and Other Cardiovascular Risk Factors in Primary Care Using the Delphi Methodology
por: Morillas Blasco, Pedro, et al.
Publicado: (2022)

Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases
por: Rodríguez Padial, Luis, et al.
Publicado: (2016)

Erratum to: Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases
por: Padial, Luis Rodríguez, et al.
Publicado: (2016)

Adherence to European Clinical Practice Guidelines for Secondary Prevention of Cardiovascular Disease: A Cohort Study
por: Pepió Vilaubí, Josep Maria, et al.
Publicado: (2018)

Metolazone Add-On Therapy in Heart Failure: A Cohort Study from Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)
por: Rahimi, Farzad, et al.
Publicado: (2021)

Patients Characteristics and Preliminary Outcomes of Heart Failure Registry in A Middle-Income Country: Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF)
por: Givi, Mahshid, et al.
Publicado: (2018)

Cardiovascular Risk in Patients with Dyslipidemia and Their Degree of Control as Perceived by Primary Care Physicians in a Survey—TERESA-Opinion Study
por: Pallarés-Carratalá, Vicente, et al.
Publicado: (2023)

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease
por: Gorriz, José Luis, et al.
Publicado: (2021)

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
por: Cannone, Valentina, et al.
Publicado: (2021)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Editorial: HF2Cancer: Exploring bidirectional interaction between cardiovascular diseases and cancer
por: Nebigil, Canan G., et al.
Publicado: (2023)

Overview of guidelines for the management of dyslipidemia: EU perspectives
por: Giner-Galvañ, Vicente, et al.
Publicado: (2016)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Decrease in the 30-day heart failure (HF) Rehospitalization Rate after the implementation of a HF managed protocol
por: Correa, AG, et al.
Publicado: (2009)

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
por: Morrow, David A, et al.
Publicado: (2019)

Inhaler Adherence in COPD: A Crucial Step Towards the Correct Treatment
por: Turégano-Yedro, Miguel, et al.
Publicado: (2023)

Gender Inequalities in Diagnostic Inertia around the Three Most Prevalent Cardiovascular Risk Studies: Protocol for a Population-Based Cohort Study
por: Carratala-Munuera, Concepción, et al.
Publicado: (2021)

Consideraciones respecto a ezetimiba y deterioro renal
por: Pallarés-Carratalá, Vicente, et al.
Publicado: (2015)

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
por: Sharma, Abhinav, et al.
Publicado: (2023)

Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study
por: Orozco-Beltran, Domingo, et al.
Publicado: (2017)

Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF
por: Rubattu, Speranza, et al.
Publicado: (2017)

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
por: Barrios, Vivencio, et al.
Publicado: (2022)

Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI‐HF trial
por: Targher, Giovanni, et al.
Publicado: (2020)

Correction: Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study
por: Orozco-Beltran, Domingo, et al.
Publicado: (2018)

Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
por: Correia, Luis Cláudio Lemos, et al.
Publicado: (2016)

The Heart Failure Optimization Study (HF-OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases
por: Dutka, Mieczysław, et al.
Publicado: (2021)

National trend of heart failure and other cardiovascular diseases in people living with human immunodeficiency virus
por: Park, Dae Yong, et al.
Publicado: (2022)

Cardiovascular Disease: The Other Face of Diabetes
por: Vlasakakis, G, et al.
Publicado: (2013)

Luces y sombras de la Guía Europea esc-2021 de Prevención de la Enfermedad Cardiovascular en la Práctica Clínica
por: Martín-Rioboó, Enrique, et al.
Publicado: (2023)

Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population
por: Straburzyńska-Migaj, Ewa, et al.
Publicado: (2015)

Non‐invasive telemedical care in heart failure patients and stroke: post hoc analysis of TIM‐HF and TIM‐HF2 trials
por: Tütüncü, Serdar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v23b99hc6d3v0tq5mo669jjguj